Venous and arterial thrombosis in COVID-19: An updated narrative review

J Infect Public Health. 2022 Jun;15(6):689-702. doi: 10.1016/j.jiph.2022.05.003. Epub 2022 May 14.

Abstract

Hospitalized patients with coronavirus disease 2019 (COVID-19), particularly those admitted to the intensive care unit (ICU) are at high risk of morbidity and mortality. Several observational studies have described hemostatic derangements and thrombotic complications in patients with COVID-19. The aim of this review article is to summarize the current evidence on pathologic findings, pathophysiology, coagulation and hemostatic abnormalities, D-dimer's role in prognostication epidemiology and risk factors of thrombotic complications, and the role of prophylactic and therapeutic anticoagulation in patients with COVID-19. While existing evidence is limited in quality, COVID-19 appears to increase micro-and macro-vascular thrombosis rates in hospitalized and critically ill patients, which may contribute to the burden of disease. D-dimer can be used for risk stratification of hospitalized patients, but its role to guide anticoagulation therapy remains unclear. Evidence of higher quality is needed to address the role of therapeutic anticoagulation or high-intensity venous thromboembolism prophylaxis in COVID-19 patients. TAKE-HOME POINTS.

Keywords: Anticoagulation; COVID-19; Critically ill; D-dimer level; Thrombosis; Venous thromboembolism prophylaxis.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • COVID-19* / complications
  • Hemostatics*
  • Humans
  • SARS-CoV-2
  • Thrombosis* / drug therapy
  • Thrombosis* / epidemiology
  • Thrombosis* / etiology

Substances

  • Anticoagulants
  • Hemostatics